Successful prenatal treatment of XXXX .

@entity1 @entity10586 @entity2990 @entity12554 @entity134 @entity619 @entity4418 @entity701
A mother carrying a fetus affected with @entity12554 received prenatal treatment with @entity619 (0.5 mg, tid, p.o.) started from the very beginning of the 8th week of gestation. Prenatal diagnosis had to rely on amniocentesis with karyotyping and @entity134 hormone determination, because HLA and DNA data from the deceased index case or direct molecular genetic techniques were not available. The pre- and postnatal diagnosis of @entity12554 was based on mass spectrometric determination of @entity4418 . @entity619 was discontinued for 5 days prior to amniocentesis. Monitoring of @entity701 , @entity2990 and @entity10586 in maternal plasma revealed suppressed maternal and fetal adrenal glands throughout pregnancy. Plasma @entity619 levels confirmed excellent maternal compliance. At term, an eutrophic @entity1 with normal female genitalia was delivered. The diagnosis of @entity12554 and salt loss was confirmed postnatally. Regarding the side-effects of @entity619 , the benefit/risk ratio was in favour of prenatal @entity619 therapy.
